Bonesupport Holding AB (publ) (0RQO.L)

231,20 -0,40 (-0,17%) Alla chiusura: 04:23PM BST

Bonesupport Holding AB (publ)

Scheelevägen 19
Lund 223 70
Sweden
46 4 62 86 53 70
https://www.bonesupport.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 118

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Emil Billbäck	Chief Executive Officer	9,68M	N/D	1970
Mr. Håkan Johansson	Chief Financial Officer	248k	N/D	1963
Mr. Michael Wrang Mortensen	Executive Vice President of Global R&D and Operations	N/D	N/D	1975
Ms. Annelie Aava Vikner	Executive Vice President of Global Marketing	N/D	N/D	1971
Ms. Helena L. Brandt	Executive Vice President of Human Resources	N/D	N/D	1965
Dr. Michael Diefenbeck M.D., Ph.D.	Executive VP of Medical & Clinical Affairs and Chief Medical Officer	N/D	N/D	1974
Mr. Fergus MacLeod	GM & Executive VP of Commercial Operations of EUROW	N/D	N/D	1970
Mr. Michael Roth	GM & Executive VP of Commercial Operations of North America	N/D	N/D	1963

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in SEK.

Descrizione

Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also offers CERAMENT Bead Tray, an adjunctive local delivery option for surgeons for targeted delivery to osseous defects and for dead space management. In addition, the company develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, and foot and ankle surgery. The company was founded in 1999 and is headquartered in Lund, Sweden.

Governance aziendale

L'ISS Governance QualityScore di Bonesupport Holding AB (publ) al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.